Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Clinical Trial ID NCT01896999

PubWeight™ 9.29^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01896999

Top papers